Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Sc-FOS for Pouchitis Prevention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02203955
Recruitment Status : Completed
First Posted : July 30, 2014
Last Update Posted : February 24, 2020
Sponsor:
Information provided by (Responsible Party):
Laura E. Raffals, M.D, Mayo Clinic

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The main objective is to compare prebiotic therapy with placebo for the prevention of pouchitis after closure of diverting ileostomy in patients with an ileal pouch anal anastomosis. This study will also characterize the effects of prebiotics on the fecal microbiota and fecal microbial metabolites and correlate these effects with the primary outcome of development of pouchitis.

Condition or disease Intervention/treatment Phase
Pouchitis Drug: Short-Chain Fructooligosaccharide Drug: Maltodextrin Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Prevention of Pouchitis With Short-Chain Fructooligosaccharide Therapy, A Double-Blind, Placebo-Controlled Trial
Actual Study Start Date : August 2014
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2018
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Short-Chain Fructooligosaccharide
4 chews (8.0 g scFOS) orally per day for 12 months
 Drug: Short-Chain Fructooligosaccharide
4 chews (8.0 g scFOS) orally for 12 months
Placebo Comparator: Maltodextrin
4 chews (maltodextrin) daily for 12 months
 Drug: Maltodextrin
4 chews (maltodextrin) daily for 12 months


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Mean Change in Pouchitis Disease Activity Index (PDAI) at One Year [ Time Frame: baseline, 1 year ]
    In the PDAI, an overall score is calculated from three separate six-point scales comprising of clinical symptoms, endoscopic findings and histological changes. The PDAI incorporates histological features of acute inflammation, and establishes a cut-off of seven for differentiation between 'pouchitis (≥7 points) and 'no pouchitis' (<7 points).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Age 18-65 years.
  2. History of ulcerative colitis
  3. Ileostomy closure after IPAA
  4. Ability to give appropriate consent

Exclusion Criteria:

  1. Crohn's disease.
  2. Perianal disease (including abscess, fissure, or stricture)
  3. Pregnancy
  4. Lactation
  5. Concurrent treatment for IBD or pouchitis
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02203955


Locations
Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Layout table for investigator information
Principal Investigator: Laura Raffals, MD Mayo Clinic
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Laura E. Raffals, M.D, Assistant Professor of Medicine, Mayo Clinic
ClinicalTrials.gov Identifier: NCT02203955    
Other Study ID Numbers: 14-001220
First Posted: July 30, 2014    Key Record Dates
Last Update Posted: February 24, 2020
Last Verified: February 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Pouchitis
Ileitis
Enteritis
Gastroenteritis
 Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Ileal Diseases